早期子宫内膜癌前哨淋巴结活检的应用趋势与结局
基于美国SEER项目2003至2018年83,139例T1期子宫内膜癌行子宫切除及淋巴结评估的女性,前哨淋巴结活检使用率从2005年0.2%升至2018年29.7%(P<.001),且与淋巴结清扫相比未增加子宫内膜癌特异性死亡率。
要点
- 前哨淋巴结活检使用率从2005年0.2%升至2018年29.7%(P<.001)。
- 子宫内膜样癌使用率0.3%–31.6%,非子宫内膜样癌0.6%–21.0%(均P<.001)。
- 前哨淋巴结活检与淋巴结清扫相比,子宫内膜癌特异性死亡率无显著增加。
核心结论
- 美国早期子宫内膜癌的手术淋巴结评估正从淋巴结清扫转向前哨淋巴结活检,未见对癌症特异性生存有负面影响的迹象。
研究设计与样本
- 观察性研究,查询美国国家癌症研究所SEER项目,纳入2003至2018年83,139例因T1期子宫内膜癌行初次子宫切除及淋巴结评估的女性。
主要发现
- 前哨淋巴结活检使用率从2005年0.2%升至2018年29.7%(P<.001)。
- 子宫内膜样癌使用率从2005至2018年为0.3%–31.6%,非子宫内膜样癌从2006至2018年为0.6%–21.0%(均P<.001)。
- 多变量分析中,更近的手术年份、子宫内膜样组织学、高分化肿瘤、T1a期病变和较小肿瘤尺寸与前哨淋巴结活检使用独立相关(P<.05)。
- 子宫内膜样肿瘤中前哨淋巴结活检与淋巴结清扫相比,子宫内膜癌特异性死亡率无显著增加(亚分布HR 0.96,95%CI 0.82–1.13)。
- 非子宫内膜样肿瘤中前哨淋巴结活检与淋巴结清扫相比,子宫内膜癌特异性死亡率无显著增加(亚分布HR 0.85,95%CI 0.69–1.04)。
临床怎么用
- 原文未据此给出推荐,仅报告前哨淋巴结活检使用增加且未显示对癌症特异性生存有负面影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine trends, characteristics, and oncologic outcomes of sentinel lymph node biopsy for early endometrial cancer. METHODS: This observational study queried the National Cancer Institute's Surveillance, Epidemiology, and End Results Program by examining 83,139 women with endometrial cancer who underwent primary hysterectomy with nodal evaluation for T1 disease from 2003 to 2018. Primary outcome measures were the temporal trends in utilization of sentinel lymph node biopsy and patient characteristics associated with sentinel lymph node biopsy use, assessed by multivariable binary logistic regression models. Secondary outcome measure was endometrial cancer-specific mortality associated with sentinel lymph node biopsy, assessed by propensity score inverse probability of treatment weighting. RESULTS: The utilization of sentinel lymph node biopsy increased from 0.2 to 29.7% from 2005 to 2018 (P<.001). The uptake was higher for women with endometrioid (0.3-31.6% between 2005 and 2018) compared with nonendometrioid (0.6-21.0% between 2006 and 2018) histologic subtypes (both P<.001). In a multivariable analysis, more recent year surgery, endometrioid histology, well-differentiated tumors, T1a disease, and smaller tumor size were independently associated with sentinel lymph node biopsy use (P<.05). Performance of sentinel lymph node biopsy was not associated with increased endometrial cancer-specific mortality compared with lymphadenectomy for endometrioid tumors (subdistribution hazard ratio [HR] 0.96, 95% CI 0.82-1.13) or nonendometrioid tumors (subdistribution HR 0.85, 95% CI 0.69-1.04). For low-risk endometrial cancer, the increase in sentinel lymph node biopsy resulted in a 15.3 percentage-point (1.4-fold) increase in surgical nodal evaluation by 2018 (expected vs observed rates, 37.8 vs 53.1%). CONCLUSION: The landscape of surgical nodal evaluation is shifting from lymphadenectomy to sentinel lymph node biopsy for early endometrial cancer in the United States, with no indication of a negative effect on cancer-specific survival.
引用
- Matsuo K, Klar M, Nusbaum DJ, et al. Utilization and Outcomes of Sentinel Lymph Node Biopsy for Early Endometrial Cancer. Obstet Gynecol. 2022. PMID: 35576340. doi:10.1097/AOG.0000000000004733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。